Geode Capital Management’s Taysha Gene Therapies TSHA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $8.77M | Buy |
3,793,572
+128,840
| +4% | +$298K | ﹤0.01% | 2446 |
|
|
2025
Q1 | $5.1M | Buy |
3,664,732
+92,383
| +3% | +$128K | ﹤0.01% | 2644 |
|
|
2024
Q4 | $6.18M | Buy |
3,572,349
+9,591
| +0.3% | +$16.6K | ﹤0.01% | 2636 |
|
|
2024
Q3 | $7.16M | Buy |
3,562,758
+682,273
| +24% | +$1.37M | ﹤0.01% | 2566 |
|
|
2024
Q2 | $6.45M | Buy |
2,880,485
+1,860,694
| +182% | +$4.17M | ﹤0.01% | 2587 |
|
|
2024
Q1 | $2.93M | Buy |
1,019,791
+34,370
| +3% | +$98.7K | ﹤0.01% | 2958 |
|
|
2023
Q4 | $1.74M | Buy |
985,421
+523,755
| +113% | +$927K | ﹤0.01% | 3159 |
|
|
2023
Q3 | $1.46M | Buy |
461,666
+103,813
| +29% | +$328K | ﹤0.01% | 3184 |
|
|
2023
Q2 | $237K | Sell |
357,853
-18,611
| -5% | -$12.3K | ﹤0.01% | 3969 |
|
|
2023
Q1 | $300K | Buy |
376,464
+44,723
| +13% | +$35.7K | ﹤0.01% | 3858 |
|
|
2022
Q4 | $749K | Buy |
331,741
+91,326
| +38% | +$206K | ﹤0.01% | 3494 |
|
|
2022
Q3 | $464K | Buy |
240,415
+2,176
| +0.9% | +$4.2K | ﹤0.01% | 3761 |
|
|
2022
Q2 | $886K | Sell |
238,239
-171,331
| -42% | -$637K | ﹤0.01% | 3484 |
|
|
2022
Q1 | $2.67M | Buy |
409,570
+18,719
| +5% | +$122K | ﹤0.01% | 3106 |
|
|
2021
Q4 | $4.55M | Buy |
390,851
+27,835
| +8% | +$324K | ﹤0.01% | 2941 |
|
|
2021
Q3 | $6.76M | Buy |
363,016
+99,574
| +38% | +$1.85M | ﹤0.01% | 2730 |
|
|
2021
Q2 | $5.58M | Buy |
263,442
+110,980
| +73% | +$2.35M | ﹤0.01% | 2823 |
|
|
2021
Q1 | $3.09M | Sell |
152,462
-11,352
| -7% | -$230K | ﹤0.01% | 3029 |
|
|
2020
Q4 | $4.35M | Buy |
+163,814
| New | +$4.35M | ﹤0.01% | 2675 |
|